2 results
Approved WMOPending
To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib
Approved WMOPending
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.